Timothy Price

List of Publications by Year in Descending Order

256 papers	14,077 citations	43 h-index	117 g-index
267 ext. papers	16,985 ext. citations	5.6 avg, IF	5.95 L-index

#	Paper	IF	Citations
256	VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.. *Scientific Reports*, **2022**, 12, 1238	4.9	1
255	The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. *Patient Education and Counseling*, **2022**, 105, 212-220	3.1	
254	Insights From the IDEA Collaboration: Are They Enough?. *Journal of Clinical Oncology*, **2022**, JCO2102975	2.2	1
253	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.. *Targeted Oncology* , **2022**, 17, 95	5	1
252	Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.. *Lancet Oncology, The*, **2021**,	21.7	18
251	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. *Expert Review of Anticancer Therapy*, **2021**, 1-13	3.5	
250	Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. *Targeted Oncology*, **2021**, 17, 35	5	0
249	Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells. *Breast Cancer Research and Treatment*, **2021**, 187, 681-693	4.4	
248	Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium.. *Journal of Clinical Oncology*, **2021**, 39, 4115-4115	2.2	
247	Sotorasib for Lung Cancers with p.G12C Mutation. *New England Journal of Medicine*, **2021**, 384, 2371-2381	59.2	168
246	Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours. *BMC Cancer*, **2021**, 21, 736	4.8	1
245	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. *International Journal of Cancer*, **2021**, 148, 1014-1026	7.5	26
244	Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. *Expert Review of Gastroenterology and Hepatology*, **2021**, 15, 203-210	4.2	2
243	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. *Current Problems in Cancer*, **2021**, 45, 100637	2.3	6
242	Expanded Low Allele Frequency and V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. *Clinical Cancer Research*, **2021**, 27, 52-59	12.9	6
241	Curative therapy for rectal cancer. *Expert Review of Anticancer Therapy*, **2021**, 21, 193-203	3.5	3
240	Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. *Asia-Pacific Journal of Clinical Oncology*, **2021**, 17, 131-138	1.9	7

239	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. *Journal of Clinical Oncology*, **2021**, 39, 17-29	2.2	22
238	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. *Clinical Cancer Research*, **2021**, 27, 2159-2167	12.9	3
237	Immunohistochemistry features and molecular pathology of appendiceal neoplasms. *Critical Reviews in Clinical Laboratory Sciences*, **2021**, 58, 369-384	9.4	1
236	Female breast cancer treatment and survival in South Australia: Results from linked health data. *European Journal of Cancer Care*, **2021**, 30, e13451	2.4	2
235	Postpancreatectomy Acute Pancreatitis (PPAP): Definition and Grading from the International Study Group for Pancreatic Surgery (ISGPS). *Annals of Surgery*, **2021**,	7.8	4
234	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. *Clinical Colorectal Cancer*, **2021**, 20, 245-255	3.8	1
233	Targeting Mutated KRAS Genes to Treat Solid Tumours.. *Molecular Diagnosis and Therapy*, **2021**, 26, 39	4.5	3
232	Anti-Angiogenic Properties of Ginsenoside Rg3. *Molecules*, **2020**, 25,	4.8	13
231	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. *Clinical Cancer Research*, **2020**, 26, 3662-3670	12.9	42
230	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. *PLoS ONE*, **2020**, 15, e0229900	3.7	9
229	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. *Expert Review of Anticancer Therapy*, **2020**, 20, 251-270	3.5	3
228	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. *Expert Review of Anticancer Therapy*, **2020**, 20, 305-324	3.5	
227	Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study. *BMJ Open*, **2020**, 10, e037069	3	2
226	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. *Cancers*, **2020**, 12,	6.6	5
225	Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. *Asia-Pacific Journal of Clinical Oncology*, **2020**, 16 Suppl 1, 3-12	1.9	1
224	CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.. *Journal of Clinical Oncology*, **2020**, 38, 4018-4018	2.2	11
223	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).. *Journal of Clinical Oncology*, **2020**, 38, 4608-4608	2.2	7
222	First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).. *Journal of Clinical Oncology*, **2020**, 38, 604-604	2.2	5

221	Phase I trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma (ART in LAP).. *Journal of Clinical Oncology*, **2020**, 38, e16796-e16796	2.2	
220	Regorafinib outcomes from the population-based South Australian mCRC registry (SAmCRCR).. *Journal of Clinical Oncology*, **2020**, 38, e19344-e19344	2.2	
219	Prognostic differences of RAS mutations: Results from South Australian (SA) metastatic colorectal (mCRC) registry.. *Journal of Clinical Oncology*, **2020**, 38, 4067-4067	2.2	1
218	Cohort 1 results of a phase I study of autolytic immunotherapy of metastatic neuroendocrine neoplasms using intralesional rose bengal disodium.. *Journal of Clinical Oncology*, **2020**, 38, e16694-e16694	2.2	
217	A systematic scoping review of determinants of multidisciplinary cancer team access and decision-making in the management of older patients diagnosed with colorectal cancer. *Journal of Geriatric Oncology*, **2020**, 11, 909-916	3.6	2
216	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. *JCO Precision Oncology*, **2020**, 4,	3.6	3
215	Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry. *Targeted Oncology*, **2020**, 15, 751-757	5	3
214	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. *Cancer Biology and Therapy*, **2020**, 21, 891-898	4.6	7
213	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. *New England Journal of Medicine*, **2020**, 383, 1207-1217	59.2	469
212	Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age. *Breast Cancer Research*, **2020**, 22, 90	8.3	8
211	Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. *Molecules*, **2019**, 24,	4.8	12
210	Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. *Targeted Oncology*, **2019**, 14, 85-91	5	8
209	Moving miRNAs to therapeutic targets in colorectal cancer. *EBioMedicine*, **2019**, 43, 13-14	8.8	1
208	AuthorsÕReply to Yu: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry". *Targeted Oncology*, **2019**, 14, 367-368	5	
207	Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	13
206	Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. *Epigenetics*, **2019**, 14, 158-170	5.7	7
205	Stereoselective Anti-Cancer Activities of Ginsenoside Rg3 on Triple Negative Breast Cancer Cell Models. *Pharmaceuticals*, **2019**, 12,	5.2	20
204	BRAF Mutation and Its Importance in Colorectal Cancer **2019**,		5

203	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. *Journal of Breast Cancer*, **2019**, 22, 341-361	3	26
202	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*, **2019**, 575, 217-223	50.4	703
201	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. *Journal of Clinical Oncology*, **2019**, 37, 11023-11023	2.2	6
200	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.. *Journal of Clinical Oncology*, **2019**, 37, 3003-3003	2.2	108
199	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2019**, 37, 3518-3518	2.2	1
198	A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.. *Journal of Clinical Oncology*, **2019**, 37, 4102-4102	2.2	2
197	Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. *Journal of Clinical Oncology*, **2019**, 37, 537-537	2.2	2
196	Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. *Journal of Clinical Oncology*, **2019**, 37, 638-638	2.2	3
195	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. *JMIR Research Protocols*, **2019**, 8, e14361	2	2
194	Type 2 diabetes as a potential risk marker for early onset colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, e15005-e15005	2.2	1
193	First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. *Asia-Pacific Journal of Clinical Oncology*, **2019**, 15 Suppl 1, 3-14	1.9	3
192	Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival. *BMJ Open*, **2019**, 9, e031421	3	12
191	SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. *BMC Cancer*, **2019**, 19, 1229	4.8	4
190	Outcomes of Older Patients (≥70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. *Clinical Colorectal Cancer*, **2019**, 18, e140-e149	3.8	4
189	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. *Clinical Colorectal Cancer*, **2019**, 18, 141-148	3.8	11
188	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. *Clinical Cancer Research*, **2019**, 25, 1216-1225	12.9	18
187	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. *Annals of Surgery*, **2019**, 269, 520-529	7.8	127
186	Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. *Expert Opinion on Biological Therapy*, **2018**, 18, 449-457	5.4	17

185	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. *Expert Review of Anticancer Therapy*, **2018**, 18, 339-349	3.5	6
184	Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia. *Hpb*, **2018**, 20, 340-346	3.8	8
183	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 263-270	18.8	75
182	Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. *Cancer Treatment Reviews*, **2018**, 66, 1-6	14.4	19
181	Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer. *Lancet Oncology, The*, **2018**, 19, 587-589	21.7	3
180	Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases". *Annals of Surgery*, **2018**, 268, e9-e10	7.8	
179	Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer: A Retrospective Cohort Study Using a Prospectively Maintained Database to Analyze Survival Outcomes for Patients With Indeterminate Extrahepatic Disease on 18FDG-PET Scan Before Liver Resection for Metastatic Colorectal Cancer. *Annals of Surgery*, **2018**, 267, 666-671	7.8	3
178	Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. *Journal of Hepato-Biliary-Pancreatic Sciences*, **2018**, 25, 96-100	2.8	88
177	Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos). *Journal of Hepato-Biliary-Pancreatic Sciences*, **2018**, 25, 87-95	2.8	121
176	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. *Acta Oncologica*, **2018**, 57, 1438-1444	3.2	48
175	The Purified Extract from the Medicinal Plant , Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis. *Cells*, **2018**, 7,	7.9	31
174	The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	19
173	Targeted therapy for metastatic colorectal cancer. *Expert Review of Anticancer Therapy*, **2018**, 18, 991-1006	3.5	31
172	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. *Future Oncology*, **2018**, 14, 2437-2459	3.6	5
171	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in Wild-Type Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2018**, 24, 3838-3844	12.9	5
170	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. *Clinical Colorectal Cancer*, **2018**, 17, e617-e629	3.8	31
169	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. *Clinical Colorectal Cancer*, **2018**, 17, 313-319	3.8	6
168	Impact of Emergent Circulating Tumor DNA Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2018**, 24, 5602-5609	12.9	25

167	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.. *Journal of Clinical Oncology*, **2018**, 36, 3500-3500	2.2	19
166	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. *Journal of Clinical Oncology*, **2018**, 36, 3534-3534	2.2	1
165	Metastatic colorectal cancer (mCRC) and micro-satellite instability.. *Journal of Clinical Oncology*, **2018**, 36, e15510-e15510	2.2	
164	Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. *Cancer Medicine*, **2018**, 7, 5478-5487	4.8	12
163	Evidence that decreased expression of sinusoidal bile acid transporters accounts for the inhibition by rapamycin of bile flow recovery following liver ischemia. *European Journal of Pharmacology*, **2018**, 838, 91-106	5.3	0
162	Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry. *Acta Oncologica*, **2018**, 57, 1455-1457	3.2	2
161	Advanced colorectal cancer treatment options beyond standard systemic therapy. *Lancet Oncology, The*, **2017**, 18, 157-159	21.7	5
160	Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. *Drugs and Aging*, **2017**, 34, 173-189	4.7	4
159	Capecitabine in locally advanced anal cancer, do we need randomised evidence?. *Expert Review of Anticancer Therapy*, **2017**, 17, 411-416	3.5	5
158	Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. *International Journal of Cancer*, **2017**, 140, 2183-2191	7.5	20
157	Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. *Expert Review of Anticancer Therapy*, **2017**, 17, 965-979	3.5	4
156	Oral versus intravenous fluoropyrimidines for colorectal cancer. *The Cochrane Library*, **2017**, 7, CD008398	5.2	15
155	Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. *Medical Care*, **2017**, 55, 86	3.1	
154	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncology, The*, **2017**, 18, 1159-1171	21.7	193
153	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. *The Cochrane Library*, **2017**, 6, CD007047	5.2	42
152	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. *Clinical Colorectal Cancer*, **2017**, 16, e73-e88	3.8	10
151	Synovial metastasis of the knee in a mutant rectal adenocarcinoma patient. *BMJ Case Reports*, **2017**, 2017,	0.9	1
150	Role of Aquaporin 1 Signalling in Cancer Development and Progression. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	58

149	A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. *Journal of Clinical Oncology*, **2017**, 35, 643-643	2.2	0
148	Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2017**, 35, 699-699	2.2	
147	Patterns of care for synchronous rectal cancer with liver-only metastasis: Results from the South Australian registry of metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2017**, 35, 701-701	2.2	0
146	Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance. *New Zealand Medical Journal*, **2017**, 130, 57-67	0.8	4
145	Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. *Clinical Colorectal Cancer*, **2016**, 15, 32-6	3.8	27
144	Liver metastases resection for gastric and esophageal tumors: is there enough evidence to go down this path?. *Expert Review of Anticancer Therapy*, **2016**, 16, 1219-1225	3.5	4
143	Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. *Annals of Surgical Oncology*, **2016**, 23, 3616-3622	3.1	11
142	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. *BMC Cancer*, **2016**, 16, 339	4.8	11
141	Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. *Journal of Experimental and Clinical Cancer Research*, **2016**, 35, 36	12.8	45
140	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. *Expert Review of Anticancer Therapy*, **2016**, 16, 557-71	3.5	2
139	Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. *Acta Oncologica*, **2016**, 55, 480-5	3.2	9
138	Optimal therapy for resectable rectal cancer. *Expert Review of Anticancer Therapy*, **2016**, 16, 285-302	3.5	
137	Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. *British Journal of Cancer*, **2016**, 114, 505-9	8.7	34
136	BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. *Molecular Diagnosis and Therapy*, **2016**, 20, 75-82	4.5	5
135	Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.. *Journal of Clinical Oncology*, **2016**, 34, 256-256	2.2	
134	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2016**, 34, 507-507	2.2	
133	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. *Journal of Clinical Oncology*, **2016**, 34, 519-519	2.2	3
132	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. *Journal of Clinical Oncology*, **2016**, 34, 3538-3538	2.2	

131	Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17.. *Journal of Clinical Oncology*, **2016**, 34, e15025-e15025	2.2	
130	Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2016**, 34, e15050-e15050	2.2	
129	BRAF Mutation in Colorectal Cancer **2016**,		1
128	Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. *Frontiers in Oncology*, **2016**, 6, 241	5.3	21
127	Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry. *Australian Journal of Rural Health*, **2016**, 24, 85-91	1.3	
126	MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial. *Journal of Medical Imaging and Radiation Oncology*, **2016**, 60, 607-615	1.7	4
125	Human intestinal spirochetosis and its relationship to sessile serrated adenomas in an Australian population. *Pathology Research and Practice*, **2016**, 212, 751-3	3.4	2
124	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. *Clinical Therapeutics*, **2016**, 38, 1376-1391	3.5	9
123	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. *Journal of Clinical Oncology*, **2016**, 34, 2258-64	2.2	41
122	Fc-Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 2435-44	12.9	24
121	Selective internal radiation therapy for liver metastases from colorectal cancer. *Cancer Treatment Reviews*, **2016**, 50, 148-154	14.4	17
120	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. *European Journal of Cancer*, **2016**, 68, 51-59	7.5	42
119	Good outcomes of liver transplantation for hepatitis C at a low volume centre. *Annals of Hepatology*, **2016**, 15, 207-14	3.1	1
118	Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?. *Cancer*, **2015**, 121, 830-5	6.4	98
117	Second-line therapy for metastatic colorectal cancer. *Lancet Oncology, The*, **2015**, 16, 476-7	21.7	
116	Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2015**, 21, 5469-79	12.9	125
115	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. *Journal of Clinical Oncology*, **2015**, 33, 3733-40	2.2	159
114	Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 1907-24	5.5	11

113	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. *PLoS ONE*, **2015**, 10, e0135399	3.7	19
112	Colorectal cancer: Metastases to a single organ. *World Journal of Gastroenterology*, **2015**, 21, 11767-76	5.6	147
111	Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer--20 Years of Progress. *Molecular Medicine*, **2015**, 21 Suppl 1, S25-31	6.2	90
110	Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. *Cancer Medicine*, **2015**, 4, 1461-71	4.8	12
109	Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.. *Journal of Clinical Oncology*, **2015**, 33, 3533-3533	2.2	1
108	Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, 3586-3586	2.2	1
107	Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.. *Journal of Clinical Oncology*, **2015**, 33, 3587-3587	2.2	1
106	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, e14623-e14623	2.2	2
105	Survival impact of primary tumor resection in patients (pts) with unresectable metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).. *Journal of Clinical Oncology*, **2015**, 33, e14675-e14675	2.2	1
104	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, 740-740	2.2	7
103	Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. *World Journal of Gastroenterology*, **2015**, 21, 5352-8	5.6	4
102	Survival for patients with resectable lung metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, 708-708	2.2	
101	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. *Journal of Clinical Oncology*, **2015**, 33, 705-705	2.2	
100	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, 566-566	2.2	
99	Survival improvement associated with access to biological agents: Updated results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.. *Journal of Clinical Oncology*, **2015**, 33, e14576-e14576	2.2	
98	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. *Lancet Oncology, The*, **2014**, 15, 569-79	21.7	314
97	Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. *Supportive Care in Cancer*, **2014**, 22, 121-8	3.9	72
96	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. *Annals of Oncology*, **2014**, 25, 117-21	10.3	38

95	Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. *Annals of Oncology*, **2014**, 25, 107-16	10.3	137
94	ASPECCT: panitumumab versus cetuximab for colorectal cancer--authorsÕreply. *Lancet Oncology, The*, **2014**, 15, e303	21.7	2
93	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. *Clinical Cancer Research*, **2014**, 20, 744-53	12.9	117
92	Can we accurately report PTEN status in advanced colorectal cancer?. *BMC Cancer*, **2014**, 14, 128	4.8	9
91	Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. *International Journal of Cancer*, **2014**, 135, 731-41	7.5	25
90	Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. *Clinical Colorectal Cancer*, **2014**, 13, 87-93	3.8	43
89	Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. *Medical Journal of Australia*, **2014**, 201, 462-6	4	6
88	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. *British Journal of Cancer*, **2014**, 110, 648-55	8.7	57
87	The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. *Acta Oncologica*, **2014**, 53, 877-84	3.2	8
86	Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. *Colorectal Cancer*, **2014**, 3, 223-232	0.8	1
85	FOLFIRI with cetuximab or bevacizumab: FIRE-3. *Lancet Oncology, The*, **2014**, 15, e582-e583	21.7	2
84	Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. *Therapeutic Advances in Gastroenterology*, **2014**, 7, 20-37	4.7	26
83	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. *Expert Review of Anticancer Therapy*, **2014**, 14, 1477-93	3.5	12
82	Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. *Annals of Oncology*, **2014**, 25, 1506-16	10.3	142
81	The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. *European Journal of Cancer*, **2014**, 50, 535-43	7.5	14
80	A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. *Supportive Care in Cancer*, **2014**, 22, 513-8	3.9	24
79	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. *Journal of Clinical Oncology*, **2014**, 32, 3501-3501	2.2	40
78	Correlation of PI3KCAand extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2014**, 32, 3539-3539	2.2	2

77	Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. *Journal of Clinical Oncology*, **2014**, 32, 3552-3552	2.2	2
76	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 3568-3568	2.2	27
75	Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.. *Journal of Clinical Oncology*, **2014**, 32, 4101-4101	2.2	9
74	Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 534-534	2.2	1
73	Right (R) or left (L) primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC): Results from the south Australian registry of mCRC.. *Journal of Clinical Oncology*, **2014**, 32, 596-596	2.2	1
72	The management of colorectal cancer (CRC) liver metastases with yttrium-90 microspheres (Y90): The south Australian (SA) experience.. *Journal of Clinical Oncology*, **2014**, 32, 666-666	2.2	1
71	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, LBA387-LBA387	2.2	20
70	KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. *Gastrointestinal Cancer Research: GCR*, **2014**, 7, 23-6		26
69	Patterns of care and outcomes for young patients (age Journal of Clinical Oncology, **2014**, 32, e17584-e17584	2.2	
68	Survival outcomes for patients with metastatic colorectal cancer (mCRC) based on primary site, right (R) colon versus left (L) colon versus rectal (Rec) primary: Results from the South Australian Registry of mCRC.. *Journal of Clinical Oncology*, **2014**, 32, 3540-3540	2.2	
67	Survival improvements associated with access to biologic agents: Results from the South Australian (SA) Metastatic Colorectal (mCRC) Registry.. *Journal of Clinical Oncology*, **2014**, 32, e17616-e17616	2.2	
66	Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.. *Journal of Clinical Oncology*, **2014**, 32, 3609-3609	2.2	
65	Medical Oncology **2014**, 71-82		
64	Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 502-502	2.2	1
63	The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in nontrial patients in two cancer centers.. *Journal of Clinical Oncology*, **2014**, 32, 595-595	2.2	
62	A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 547-547	2.2	
61	The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. *BMC Cancer*, **2013**, 13, 242	4.8	8
60	Management of gastric cancer in Asia: resource-stratified guidelines. *Lancet Oncology, The*, **2013**, 14, e535-47	21.7	344

59	Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. *Asia-Pacific Journal of Clinical Oncology*, **2013**, 9, 239-48	1.9	5
58	Panitumumab in metastatic colorectal cancer. *Expert Review of Anticancer Therapy*, **2013**, 13, 781-93	3.5	4
57	Current opinion on optimal treatment for colorectal cancer. *Expert Review of Anticancer Therapy*, **2013**, 13, 597-611	3.5	24
56	A population-based study of metastatic colorectal cancer in individuals aged ≥80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. *Cancer*, **2013**, 119, 722-8	6.4	33
55	Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. *Acta Oncologica*, **2013**, 52, 1699-706	3.2	17
54	Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2013**, 36, 49-52	2.7	24
53	Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. *Annals of Oncology*, **2013**, 24, 953-60	10.3	40
52	Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. *Cancer Medicine*, **2013**, 2, 277-85	4.8	28
51	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. *Journal of Clinical Oncology*, **2013**, 31, 2477-84	2.2	107
50	Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?. *British Journal of Cancer*, **2013**, 109, 1338-43	8.7	22
49	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.. *Journal of Clinical Oncology*, **2013**, 31, 3531-3531	2.2	25
48	A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).. *Journal of Clinical Oncology*, **2013**, 31, e14506-e14506	2.2	1
47	Hepatic encephalopathy associated with cancer or anticancer therapy. *Gastrointestinal Cancer Research: GCR*, **2013**, 6, 11-6		11
46	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. *Journal of Clinical Oncology*, **2013**, 31, e14501-e14501	2.2	
45	"Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?. *Asia-Pacific Journal of Clinical Oncology*, **2012**, 8, 10-3	1.9	8
44	Guillain-Barre syndrome in colorectal cancer. *Asia-Pacific Journal of Clinical Oncology*, **2012**, 8, 205-8	1.9	3
43	Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. *Investigational New Drugs*, **2012**, 30, 2303-17	4.3	110
42	Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. *Clinical Colorectal Cancer*, **2012**, 11, 247-54	3.8	55

41	Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice. *Cancer Treatment Reviews*, **2012**, 38, 397-406	14.4	61
40	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. *European Journal of Cancer*, **2012**, 48, 1293-8	7.5	19
39	Age and treatment choices in advanced colorectal cancer. *Colorectal Cancer*, **2012**, 1, 343-351	0.8	
38	A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection. *Biochimie*, **2012**, 94, 2491-7	4.6	9
37	Cetuximab in metastatic colorectal cancer. *Expert Review of Anticancer Therapy*, **2012**, 12, 555-65	3.5	27
36	Management of advanced gastric cancer. *Expert Review of Gastroenterology and Hepatology*, **2012**, 6, 199-208; quiz 209	4.2	61
35	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. *Colorectal Cancer*, **2012**, 1, 137-148	0.8	1
34	Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.. *Journal of Clinical Oncology*,	2.2	10
33	Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2012**, 30, 387-387	2.2	8
32	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. *Journal of Clinical Oncology*, **2012**, 30, 388-388	2.2	6
31	Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study.. *Journal of Clinical Oncology*, **2012**, 30, e19513-e19513	2.2	
30	South Australian clinical registry for metastatic colorectal cancer. *ANZ Journal of Surgery*, **2011**, 81, 352-7	1	43
29	Small cell lung cancer: patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit. *Asia-Pacific Journal of Clinical Oncology*, **2011**, 7, 252-7	1.9	4
28	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. *BMC Cancer*, **2011**, 11, 313	4.8	9
27	Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. *Clinical Proteomics*, **2011**, 8, 16	5	25
26	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. *Journal of Clinical Oncology*, **2011**, 29, 2675-82	2.2	168
25	Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. *Journal of Clinical Oncology*, **2011**, 29, 1465-71	2.2	526
24	Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. *Annals of Oncology*, **2011**, 22, 1834-8	10.3	35

23	Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. *Medical Journal of Australia*, **2010**, 193, 46-52	4	74
22	Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2010**, 304, 1073-81	27.4	958
21	Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. *Journal of Clinical Oncology*, **2010**, 28, 3191-8	2.2	318
20	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2010**, 28, 4706-13	2.2	789
19	Antitumor effect of somatostatin analogs in neuroendocrine tumors. *Journal of Clinical Oncology*, **2010**, 28, e41-2; author reply e43-4	2.2	7
18	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. *Clinical Colorectal Cancer*, **2010**, 9, 8-14	3.8	7
17	Reversing Hyperammonemia in Neuroendocrine Tumors. *Journal of Clinical Gastroenterology*, **2010**, 44, e186-9	3	6
16	Oral versus intravenous fluoropyrimidines for colorectal cancer **2010**,		2
15	Epidemiology of neuroendocrine cancers in an Australian population. *Cancer Causes and Control*, **2010**, 21, 931-8	2.8	24
14	Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. *Oncologist*, **2009**, 14, 29-39	5.7	60
13	Response to: Perioperative Morbidity Affects the Long-Term Survival in Patients Following Liver Resection for Colorectal Metastases. *Journal of Gastrointestinal Surgery*, **2009**, 13, 180-180	3.3	
12	Selective internal radiation therapy for liver metastases from colorectal cancer. *The Cochrane Library*, **2009**, CD007045	5.2	15
11	Contrast induced hyperthyroidism due to iodine excess. *BMJ Case Reports*, **2009**, 2009,	0.9	3
10	K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *New England Journal of Medicine*, **2008**, 359, 1757-65	59.2	2912
9	Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. *Archives of Surgery*, **2008**, 143, 313-4		5
8	Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer **2008**,		5
7	Fluorouracil-induced hepatic artery spasm preventing yttrium-90 microsphere administration. *Clinical Nuclear Medicine*, **2008**, 33, 528-30	1.7	2
6	A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. *Investigational New Drugs*, **2008**, 26, 89-94	4.3	65

5	Successfully improving access and accrual to oncology clinical trials. *Cancer*, **2007**, 109, 1451-3	6.4	3
4	Cetuximab for the treatment of colorectal cancer. *New England Journal of Medicine*, **2007**, 357, 2040-8	59.2	1587
3	Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. *Journal of Clinical Oncology*, **2007**, 25, 102-9	2.2	196
2	Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. *Leukemia and Lymphoma*, **2007**, 48, 1702-11	1.9	83
1	Chronomodulated chemotherapy in advanced colorectal carcinoma. *Journal of Clinical Oncology*, **2002**, 20, 3937-8; author reply 3938-9	2.2	2